Position
Renaissance Technologies in Dyne Therapeutics, Inc.
Back to the book · All holders of DYN
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark $1.47M$18.13 → $22.21
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 470.6K | $9.21M | — | — | — | 0.0% |
| Q1 2026 | 533.6K | $9.67M | $18.13 | −$673K | $1.14M | 0.0% |
| Q2 2026 | 360.6K | $8.01M | $22.21 | $1.47M | −$3.14M | 0.0% |